Jiri T.
- Country
- Czechia
- Department
- NA
Research Overview
- Pumitamig and Combination Therapy Versus Bevacizumab and Combination Therapy in Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Phase 3 Randomized Trial of Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
- Evaluation of Safety and Efficacy of Telisotuzumab Adizutecan Combinations in Metastatic Colorectal Cancer: A Phase 2 Open-Label Randomized Study
Data & Insights
Has run more than one trial at 57 of 180 partner sites.
Specializations
Colorectal Cancer Research
This investigator specializes in advanced treatment approaches for metastatic colorectal cancer, with particular emphasis on patients exhibiting specific genetic markers.
- Microsatellite Instability High (MSI-H) Cancer
- Mismatch Repair Deficient Tumors
- Metastatic Disease Management
The investigator focuses on evaluating innovative therapeutic strategies for colorectal cancer treatment.
Immunotherapy Applications
The investigator explores immunotherapy approaches in colorectal cancer treatment, particularly examining the effectiveness of various therapeutic combinations.
- Monotherapy Protocols
- Combination Immunotherapy
- Treatment Response Assessment
Their work includes evaluation of immunotherapy agents in different treatment settings.
Precision Medicine
The investigator's research encompasses personalized treatment strategies based on specific genetic and molecular markers in colorectal cancer.
- Biomarker-Driven Therapy
- Genetic Profiling
- Treatment Selection Criteria
Their work contributes to advancing personalized medicine approaches in oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.